Fungal Keratitis: Recent Advances in Diagnosis and Treatment by Suman, Suwarna et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Fungal Keratitis: Recent Advances 
in Diagnosis and Treatment
Suwarna Suman, Arushi Kumar, Indu Saxena  
and Manoj Kumar
Abstract
Fungal keratitis or fungal corneal ulcer is potentially blinding infection of 
cornea, is considered one of the major cause of ocular morbidity, particularly in 
developing countries. It is a common cause of infectious keratitis, especially in 
tropical and subtropical countries. Fungal keratitis is notoriously challenging to 
diagnosis and difficult to treat. Delay in diagnosis may result in irreversible sequelae 
of corneal fungal infections, which can be preventable. Fungal keratitis often have 
worse treatment outcomes than bacterial keratitis, Delayed diagnosis and scarcity of 
effective antifungal agents are the major factors for poor outcome. In the recent years 
considerable advancement in the diagnosis and treatment has been occurred. In this 
chapter, we will discuss the recent advances in diagnosis and management of fungal 
keratitis with a brief discussion on pathogenesis and future therapeutic models.
Keywords: infectious keratitis, fungal keratitis, confocal microscopy,  
polymerase chain reaction, metagenomics deep sequencing, voriconazole, posaconazole
1. Introduction
Infectious keratitis is an inflammation of the cornea caused by microorganism. 
It is most commonly associated with bacterial, fungal or viral microorganisms that 
invade into the corneal stroma, resulting in inflammation and destruction of these 
structures; ultimately leading to visual impairment and blindness. Fungal keratitis 
(FK) or keratomycosis is one of the most challenging to diagnose and difficult to 
treat. The prevalence of fungal keratitis is variable depending upon the geographic 
location. It is more common in tropical and subtropical areas and relatively rare in 
temperate countries. It is reported about 1–60% of all cases of microbial keratitis 
in various studies [1–3]. A recent review including 37 countries reported highest 
proportion in Vietnam (59.58%) followed by Paraguay (58%) [2–4]. The fungi that 
commonly cause infection of the cornea include Fusarium, Aspergillus, Curvularia, 
Bipolaris, and Candida [1, 2, 5].
Most of the currently available antifungal medications have limitations, such as 
poor bioavailability and limited ocular penetration, especially in cases with deep 
keratitis [6–8]. This results in slow resolution of fungal infections. In addition, 
fungi can penetrate deeper into corneal stroma and Descemet membrane, therefore 
more difficult to eradicate. Surgical excision of the infected cornea is required to 
control the infection in nonresponsive cases [9–12]. In recent years, considerable 
research is being continue in the field of management of fungal keratitis and several 
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newer antifungal agents and drug delivery techniques are being evolved to over-
come these limitations and improve outcome. In this chapter, we discuss the recent 
advances in diagnosis and treatment of fungal keratitis with a brief discussion on 
pathogenesis and future considerations.
2. New aspects of pathogenesis
Pathogenesis of FK has not been fully elucidated. Recent studies and advances 
have contributed in better understanding of the complicated process and host 
immune response.
2.1 Risk factors
The common risk factors for fungal keratitis are trauma with vegetative matter 
or objects contaminated with soil, contact lenses, ocular surface disease, lacrimal 
duct occlusion, fungal skin infections, long-term use of antibiotics or steroids 
locally or systemically [2, 13–17]. Other relatively rare risk factors include history of 
eye surgery, herpes simplex virus keratitis, eyelid abnormalities, etc. [18, 19].
Still in developing countries, the most common risk factor for fungal keratitis is 
ocular trauma but in developed countries, contact lens emerged as more common 
risk factor. This change has been occurred due to industrialization of farming and 
increase use of contact lens in developed world. In a large case series of 695 cases 
with fungal keratitis reported from 10 tertiary eye care centres across the United 
States over a 7-year period, 283 (40.71%) cases involved the use of contact lens 
[1]. Similarly Keay et al. in a multicentre case series of 733 cases from 11 tertiary 
care centres across the United States reported that 37% cases were associated with 
refractive contact lens wear, 25% were associated with ocular trauma, and 29% were 
associated with ocular surface disease [20].
In a study, the storage of the anti-microbial agent alexidine in its plastic containers 
at higher than room temperatures was found as the reason for decreased effectiveness 
[21]. This temperature difference in the plastic containers led to decreased concentra-
tion of the agent in solution (2.8 times less) and a corresponding higher concentration 
in the walls of its plastic containers (3.1 times higher) [22]. The lens type and its soak-
ing time significantly influences the fungicidal activity of cleaning and storage solu-
tions and poor compliance significantly increase the risk of contamination [23, 24].
2.2 Causative fungi
A review article found about 144 species of fungi from 92 genera as causative 
agents in keratitis, showing largest diversity; whereas 77 species from 42 genera 
of bacteria, 12 species from 4 genera of protozoa and only 4 types of viruses were 
implicated in infectious keratitis. However, in the majority of cases of FK the 
causative organism belong to a few genera: Fusarium, Aspergillus, and Candida 
[25]. Other fungi implicated in mycotic keratitis are Curvularia, Alternaria, and 
Penicillium [2, 13, 14]. The rarely reported fungal pathogens include Lasiodiplodia 
theobromae, Cylindrocarpon species, Metarhizium anisopliae, Paecilomyces spe-
cies, and Pythium insidiosum [15, 26–29].
2.3 Host immune response
Fungal infections initiates with adhesion of fungal cells with epithelial surfaces. 
Fungi produce various surface proteins to contribute to the adhesion to the corneal 
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epithelium, which has potential fungal binding sites such as laminins, fibronectins, 
and collagens [30, 31]. Alterations of the corneal surface due to trauma or other 
predisposing condition result in easy invasion of organisms deeper into underlying 
layers, which leads to an innate and adaptive immune-mediated inflammation, 
resulting in subsequent tissue necrosis of the surrounding area, consequently leads 
to further tissue damage, scarring, and opacification of the cornea.
2.3.1 Cytokines and innate immunity
The contact between fungi and host, result in expression of pattern recognition 
receptors (PRRs) on host epithelial and immune cells, which recognize the fungi. 
PPRs are Toll-like receptors (TLRs, including TLR2 and TLR4), C-type Lectin 
receptors (CLRs, including Dectin-1, Dectin-2 and Mincle). Dectin-1 recognizes 
β-glucan in fungal cell wall, while Dectin-2 and Mincle recognize mannan of cell 
wall [32]. Candida albicans and Aspergillus fumigatus encounter during fungal 
keratitis have been reported to be sensed by TLR [33–35]. Activated TLRs in corneal 
epithelium induce production of CXC chemokines and recruit neutrophils (are 
more than 90% of the infiltrating cells). Neutrophils are predominant source of 
mature interleukin-1β (IL-1β) and acidic mammalian chitinase (AMCase) in cor-
neas, which can inhibit the hyphal growth [36, 37]. The increased expression and 
the activation of PPRs in response to A. fumigatus with resultant increased secretion 
of inflammatory cytokines (IL-1β, IL-6, IL-8, IL-17 and IL-23) in human corneal 
epithelial cells and neutrophils is reported [38]. Increased production of reactive 
oxygen species (ROS) in response to increased levels of IL-1β, TLR4, Dectin-1 and 
LOX-1, facilitates the fungal killing [39, 40].
Leal et al. found that neutrophils produced NADPH oxidase to control the 
growth of fungi. The antifungal activity of neutrophils depended on CD18, and 
inhibiting thioredoxin, an antioxidant increased the sensitivity of fungal hyphae to 
neutrophil-mediated killing in vitro [41]. The expression of PPRs, promote the pro-
duction of pro-inflammatory cytokines, as well as the recruitment of neutrophils 
that can also cause serious inflammatory damages to cornea leading to opacification 
[32, 40, 42]. In fungal keratitis, the levels of pro-inflammatory IL-1β, IL-6, IL-8, 
IL-17, IL-23 and IFN-γ in aqueous humor were significantly higher in comparison 
to the non-keratitis control group [38]. A study among a Han Chinese population of 
patients with FK compared controls found a particular TLR4 allele that was associ-
ated with an increased risk of developing FK [43].
Fungi can produce enzymes that degrade physical barriers and facilitate tissue 
invasion. The mycotoxins produced from Fusarium species can inhibit immunity, 
break down tissues, and promote the fungal survival in host. Corneal epithelial cells 
can be destroyed by some cytosolic proteins and peptide toxins produced by fungi 
[44]. The protease and phospholipase activities detected in A. flavus and F. solani 
isolated from human eyes and their role in causation of ulceration in fungal kerati-
tis, are reported in several studies [45, 46].
2.3.2 Autophagy
Autophagy is a lysosome-mediated degradation process, which regulates intra-
cellular homeostasis of eukaryotes by mediating the degradation of proteins and 
organelles [47]. It can be activated in response to starvation, stress, hypoxia, tumor, 
and infection [48]. Autophagy is proved to be involved in immune responses, a 
previous study found that autophagy maintains the cellular and immune homeosta-
sis during the Candida albicans infection [49]. Autophagy can regulate IL-1β release 
in human primary macrophage to resist the fungal infection [50].
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A study by Li C et al. reported that the progression of FK caused by A. fumigatus 
result in increased expression of autophagy and the severity of A. fumigatus kerati-
tis, aggravated with inhibition of autophagy. The induction of autophagy reduced 
the severity of keratitis via regulating the recruitment of PMNs, balancing the 
pro-inflammatory and anti-inflammatiory cytokines release, and possibly affecting 
the differentiation of neutrophils. Autophagy may become a novel target for the 
treatment of FK in future. Further studies may add our understanding regarding 
the protective role of autophagy in FK [51].
2.4 Fungal biofilm
Biofilm formation is one of the primary mechanisms through which fungi 
evade the immune response and establish infection. Clinical isolates of Fusarium, 
Candida and Aspergillus have been shown to form biofilms. A study reported 
that F. solani formed a biofilm in vitro by 24 h while other species (Cladosporium 
sphaerospermum and Acremonium implicatum) formed at 48 h. A time-dependent 
decrease in efficacy for all six antifungal agents (amphotericin B, voriconazole, 
itraconazole, fluconazole, terbinafine, and natamycin) is reported with increase in 
minimum inhibitory concentration (MIC) of all six antifungal agents tested with 
the development of biofilm [52]. This suggests that an ability to disrupt the biofilm 
may prove useful in increasing antifungal efficacy.
3. Recent advances in diagnosis
3.1 Clinical diagnosis
Fungal keratitis can be diagnosed based on characteristic clinical features. 
Patients with keratitis usually present with sudden onset of pain, photophobia, 
watering and discharge and reduced vision. In fungal keratitis, symptoms are much 
milder than the signs [53].
A fungal keratitis classically presents as a dry, raised lesion with crenate or 
feathery borders, presence of satellite lesions and a hypopyon. An immune ring of 
Wesseley may be visible due to deposition of immune complexes and inflammatory 
cells around the ulcer (Figures 1–5). However, a study reported that Clinicians could 
correctly distinguished the microbial kingdom for 54 (73%) of 74 culture-positive 
infections, including 41 (79%) of 52 bacterial keratitis, 5 (38%) of 13 fungal 
Figure 1. 
Plaque-like ulcer with slightly defined margins, marked conjunctival injection and chemosis; fungal isolate- 
candida albicans.
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Figure 2. 
A dry looking lesion with greyish white raised exudate appearing as plaque with hypopyon in a 56-year-old 
male with fugal keratitis from Aspergillus.
Figure 3. 
A greyish white infiltrate with feathery borders and a satellite lesion in a case fungal keratitis caused by Fusarium.
Figure 4. 
Severe fungal keratitis with feathery edges in case Fusarium Keratitis.
Figure 5. 
Corneal thinning and necrosis in severe fungal keratitis caused by Fusarium in a 48-year-old male with history 
of topical steroid instillation.
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keratitis, and 8 (89%) of 9 amoebic keratitis correctly [54]. In a photographic sur-
vey, clinician were able to distinguish between bacterial and fungal aetiologies 66% 
of the time. In 39 cases of fungal keratitis, the clinicians predicted genus in 27% of 
cases and species in 7.9% of cases [55].
3.1.1 Confocal microscopy
In vivo confocal microscopy (IVCM) of the cornea has been emerged as clini-
cally useful non-invasive technique for early diagnosis of FK. It produces images 
from the cornea with a resolution of one micrometer (μm), which is enough for 
imaging of microorganisms larger than one μm, such as Acanthamoeba cysts and 
fungal hyphae [56]. This provides rapid and reliable diagnosis however, a clinical 
consensus in the interpretation of IVCM images is still lacking.
IVCM can directly visualize filamentous fungi within the whole cornea of 
patients. Confocal microscopy in vivo uses serial images to create optical sections 
through the full-thickness of the living cornea. It allows rapid identification of 
fungi and can be used to differentiate between fungal species.
Brasnu et al. diagnosed all the cases of suspected fungal keratitis (five out 
of five) caused by different fungal species using IVCM with sensitivity equal to 
the direct microscopy and culture [56]. They analyzed IVCM images of keratitis 
obtained using the Heidelberg Retina Tomograph (HRT) II confocal microscope 
(Heidelberg Engineering, Heidelberg, Germany) in five patients (four patients with 
Fusarium soloni and one patient with Candida albicans infection), and three donor 
corneas with Aspergillus fumigatus, F. solani, and C albicans infection. F. soloni 
hyphae seen as high contrast lines 3–5 microns (µm) in diameter, 200–300 µm in 
length, with a branching angle of 90° in IVCM images from patients as well as from 
the infected donor cornea. A. fumigatus hyphae seen as numerous high-contrast 
lines 200–300 µm in length and 3–5 µm in width, with the branching angle 45° in 
the infected donor cornea. C albicans-infected patient’s cornea revealed numerous 
high-contrast elongated particles measuring 10–40 µm in length and 5–10 µm in 
width. C albicans-contaminated donor cornea revealed numerous characteristic 
high-contrast elongated particles measuring 10–40 µm in length and 5–10 in µm in 
width, consistent with Candida pseudofilaments [56].
The hyper-reflective elements seen on IVCM must be differentiated from the 
basal corneal epithelial nerves, which have a more regular branching pattern. 
Stromal nerves, on the other hand, are much larger in diameter (25–50 μm). There 
are now several studies reported the use of IVCM in diagnosis and monitoring of 
treatment of fungal keratitis with reported sensitivity of 80–94% [57–60].
IVCM is a noninvasive in vivo technique useful for early identification of fungal 
elements, monitoring and guidance of treatment, and determination of the depth 
of infection. The limitation of IVCM are that technique is extremely user-depen-
dent, need a skilled operator and experienced viewer. The dense corneal infiltrates 
or scarring could preclude proper tissue penetration and visualization.
3.2 Laboratory diagnosis
Conventional methods for the diagnosis of fungal keratitis include staining of 
tissue scrapings with Gram-stain, 10% potassium hydroxide (KOH) wet mount, 
lactophenol cotton blue, Giemsa, or calcofluor white. Reported sensitivity of Gram 
staining is in the range of 36–50% [61]. KOH is a rapid and an inexpensive and 
one of the most commonly performed procedures for detection of fungi with a 
sensitivity of 61–94% and specificity of 91–97% for detecting fungus (Figure 6). 
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Lactophenol cotton blue mounts had reported sensitivity of 85% and specificity of 
90–91% [62]. Sabouraud dextrose agar medium is considered as a culture medium 
of choice for isolating fungi however it cause delay in diagnosis. Initial growth 
occurs within 72 hours in 83% of cultures and within 1 week in 97% of cultures 
[63]. Sometimes it may be necessary to wait for two weeks to confirm no growth 
in culture. Over the last decade, a number of newer methods have been devised for 
detection of fungi.
3.2.1 Polymerase chain reaction
Polymerase chain reaction (PCR) involves repeated cycles of denaturation, 
amplification, and replication, in which segments of deoxyribonucleic acid (DNA) 
are continuously multiplied. Specific DNA primers are employed to indicate the 
presence of the microorganism in question [64]. PCR has emerged as a sensitive and 
specific test for the diagnosis of fungal keratitis. Several techniques of PCR have 
been evolved and currently used for identification of fungi.
Traditional PCR by using single pair of primer to amplify the target genomic 
sequence is simple and efficient technique, but generation of nonspecific products 
can affect the results. In Nested PCR, two pairs of primers are used; one set of 
primer is an amplified sequence, and the other is complementary to the sequence 
amplified by the first one. It is more specific than traditional PCR; amplifies only 
the specific sequences looked for; but identify a set of fungal pathogens, not a single 
specific species.
In multiplex PCR Multiple primer, pairs are used. Advantage is Rapid amplifi-
cation of multiple sequences, conserves template DNA, and minimizes expense; 
recognizes many pathogens at once. In real time PCR, one set of primers is used; 
amplified sequence is linked with a fluorescent probe, which emits light when 
bound to the amplified product. It is more specific, sensitive, and reproducible but 
not ideal for multiplexing [65–67].
PCR reported higher sensitivity in comparison to culture and stains for both 
bacteria and fungi [68, 69]. Zhao et al. reported significantly higher positive detec-
tion rate of PCR for fungal keratitis (84.5%) as compare to the positivity rate for 
culture (35.3%) and stain (64.7%) [69]. A higher sensitivity of PCR for infectious 
keratitis compared to culture (98% versus 47%), but a slightly lower specificity 
(83% versus 100%) is reported in this study [69].
The PCR is rapid test, it takes 4–8 h, and only a small clinical sample is needed 
for diagnosis [7]. The limitation of PCR is that it is expensive, not readily available 
and specificity is lower than culture. Extraction of artifacts and amplification of 
Figure 6. 
Fungal hyphae in KOH wet mount counterstained with methylene blue.
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non-pathogenic DNA can lead to over diagnosis [66]. However, it can be used to 
detect fungal DNA in corneal scrape material, to start antifungal therapy at an early 
stage of the keratitis.
3.2.2 Metagenomic deep sequencing
Metagenomic deep sequencing (MDS) is a new technique for the diagnosis of 
FK; with next generation sequencing rapid and accurate diagnosis is possible. Next 
generation sequencing is high-throughput sequencing methods where billions of 
nucleic acid fragments can be sequenced simultaneously and independently. MDS is 
an unbiased approach that interrogates all genomes in a clinical sample and identify 
any organism whereas PCR is a targeted test the clinician must know the suspected 
causative organism.
It has been shown to enhance detection of common and unusual pathogens 
from the intraocular fluid of patients with infectious uveitis and other systemic 
infections [70–72]. A study by Seitzman et al. in a case series of nine patients 
of infectious keratitis diagnosed by conventional methods reported that MDS 
detected all the microorganisms identified by culture or PCR. MDS was able to 
identify parasitic, fungal, bacterial, and viral infections as a single assay. The 
pathogenic organisms ranged in size from smaller genomes (herpes simplex virus-1 
and adenovirus) to larger genomes (Acanthamoeba and Aspergillus). In one case, 
the MDS identified the organism not supposed to be a cause of infectious keratitis. 
The case was culture positive for Purpureocillium lilacinum was identified as the 
second most abundant organism and, the most abundant organism in the sample 
was Auricoccus indicus, which is not known to cause ocular infections and not 
even listed in the University of California San Francisco’s mass spectrometry’s 
database for identifiable organisms [73].
4. Recent advances in medical treatment
Polyenes (Amphotericin B and Natamycin) and azoles (fluconazole, itraconazole, 
ketoconazole, miconazole, voriconazole, and posaconazole) constitute two major 
classes of antifungal drugs used to treat ocular fungal infections including fungal 
keratitis. In Comparison to antibacterial agents, antifungals have a lower efficacy due 
to their mechanism of action (usually fungistatic, with dose dependent fungicidal 
action), lower tissue penetration, and the indolent nature of the fungal infection 
[74]. Still for the management of fungal keratitis, the traditional anti-fungal drugs 
like natamycin and fluconazole in topical and oral form are used most commonly. In 
recent years, other new drugs and drug delivery system to increase bioavailability of 
drugs have been evaluated. Anti-fungal agents are summarized in Table 1.
4.1 Natamycin
Natamycin is first antifungal agent approved for FK by Food and Drug 
Administration in the 1960s. After that, many antifungal agents have been evalu-
ated, no single agent has emerged as the best and most cost effective agent [7]. 
Cochrane systematic review in 2008 and 2012, found no evidence that any single 
drug, or combination of drugs, is more effective in the management of fungal kera-
titis. The trials included in this review were of variable quality and were generally 
underpowered [75, 76].
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Amphotericin B Topical 1.5-5 mg/ml
*IS 5-10 μg
*IC 5-10 μg/0.1 ml
First line therapy for 
Candida species. Good to 
moderate activity against 
filamentous fungi.
Deep keratitis with partial 
response to topical therapy
Not commercially 
available.
Side effects: cataract, 
transient iritis and 
corneal oedema
Natamycin Topical 5% (50 mg/
ml)
suspension
First choice for Fusarium,
Good activity against 






Econazole Topical 2% Effective against Fusarium, 





Miconazole Topical 10 mg/ml
*SC 1.2 to 10 mg
Effective against candida
Adjuvant with topical 
therapy in patients with 
low
compliance












Fluconazole Topical 0.2 %
SC 2 mg/1 ml
Oral 100-400 mg/
day oral
Effective against yeast, 
less effective against 
filamentous fungi
Good intraocular 
penetration used as 









Aspergillus, Candida, less 
effective against Fusarium
As adjuvant with topical 
therapy in deep keratitis/ 
intraocular involvement 
by yeasts
Less effective than 
natamycin
Lower bioavailability, 
and penetration into 
ocular tissues than 
other azoles
Voriconazole Topical 1-2%
IS 50 μg/0,1 m
IC 50μg/0,1 m
Oral 200 mg **BID
Broad spectrum, FK 
resistant to polyenes/ 
first-line triazoles.
Deep keratitis and 
Intraocular involvement
Less effective than 
natamycin
Side effects- blurred 




Posaconazole Topical 100 mg/ml; 
40 mg/ml
Oral 200 mg **QID/ 
400 mg BID
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Natamycin is a polyene antifungal drug, it binds preferentially to ergosterol on 
the fungal plasma membrane and causes localized membrane disruptions by alter-
ing membrane permeability. Natamycin is currently considered the most effective 
medication against Fusarium and Aspergillus [7]. Cochrane systematic review in 
2015 found that there is evidence that natamycin is more effective than voriconazole 
in the treatment of fungal ulcers. However, the trials included in this review were of 
variable quality and were generally underpowered. Future research should evaluate 
treatment effects according to fungus species [77].
Several studies reported that fungal keratitis due to fusarium responded better 
to Natamycin as compare to itraconazole and voriconazole [77]. NTM is the treat-
ment of choice for filamentous keratitis, especially that due to Fusarium species. 
However its poor penetration into corneal stroma, limits its use in deep stromal 
keratitis. In deep keratitis or with involvement of intraocular structures, natamy-
cin should be associated with other antifungal agents using a different route of 
administration.
4.2 Amphotericin B
Amphotericin B is the first broad-spectrum antifungal agent, produced by the 
actinomycetes, Streptomyces nodosus. It acts by binding to ergosterol and by promot-
ing oxidative action on cells, thus altering their metabolic functions. This binding 
also results in formation of pores or channels in the fungal cell membrane and 
increasing cell permeability. Its binding to cholesterol in human cells is responsible 
for its side effects. It is effective against Aspergillus and Candida species but less 
effective against Fusarium species [74]. It is administered as a topical solution in 
concentration of 1.5 to 5 mg/ml.
Amphotericin B has poor ocular penetration after intravenous administration 
and is toxic to human cells at a higher dose. Due to systemic (nephrotoxicity) and 
ocular toxicity (punctate epithelial erosions and greenish discoloration of the cor-
nea), amphotericin B is not currently a first line agent in treating fungal keratitis. 





Flucytosine Topical 10 mg/ml Synergistic effect with 
topical Amphotericin B in 
FK due to yeasts
Narrow spectrum/ low 
penetration into ocular 
tissues
Echinocandins
Capsofungin Topical 0.5% Yeasts resistant to polyenes 
and first-line triazoles
Limited information




Terbinafine Topical 0.5 %
Oral 250 mg/day




*IC: Intracameral, IS: Intrastromal, SC: Subconjunctival.
**BID: Twice a day, QID: for times a day.
Table 1. 
Summary of antifungal agents used in Fungal Keratitis
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In a study, Morand K, et al. compared the commercial 0.15% Amphotericin B with 
a liposomal formulation and found that the liposomal form was more stable and 
less toxic. The liposomal formulation also increased the potential amount of loaded 
drug by 3-fold compared with the conventional form [78].
4.3 Fluconazole
Fluconazole is a synthetic bistriazole available in oral, topical, and IV prepara-
tions. It has good intraocular penetration with low side effect. It shown to have 
excellent absorption from the gastrointestinal tract. Its plasma concentrations 
with oral use reach almost the same levels as with intravenous administration. 
Intraocular Penetration is effective, with aqueous concentrations similar to those in 
the plasma [74, 79]. Topical 0.2% fluconazole is effective against Candida keratitis 
with deep lesions. Oral fluconazole in a dose of 200 to 400 mg per day effective as 
an adjuvant with other topical antifungal agents.
4.4 Voriconazole
Voriconazole, a newer-generation triazole, with excellent ocular penetration 
and broad spectrum. Most of fungal isolates commonly implicated in keratitis were 
found to be susceptible to voriconazole.
Voriconazole has been reported to be effective in the treatment of fungal kera-
titis caused by different species and in cases not responding to other antifungal like 
natamycin and amphotericin [79–85]. Voriconazole has good intraocular penetra-
tion following oral administration. Advantage of oral administration is that it may 
provide steadier drug levels at the site of infection. Theil et al. compared aqueous 
samples after topical and oral voriconazole found that topical administration of 
voriconazole resulted in highly variable aqueous concentrations with troughs well 
below the minimum inhibitory concentration at which 90% of fungal isolates are 
inhibited (MIC90). Whereas, oral voriconazole provided relatively constant thera-
peutic concentration [84]. Many case reports reported successful treatment with 
topical voriconazole in conjunction oral or intravenous voriconazole [85, 86].
4.5 Posaconazole
Posaconazole is a new triazole, a synthetic structural analogue of itraconazole. 
It is available as an oral suspension (40 mg/ml), administered at a dose of 200 mg 
four times daily or 400 mg twice daily. Now also available as delayed release 
tablets (100 mg) and injection (18mg/ml). In vitro and in vivo studies showed that 
posaconazole has a broad spectrum against Candida spp., Cryptococcus neoformans, 
Aspergillus spp., and Fusarium spp. etc. and effective against most agents resistant 
to itraconazole and fluconazloe [87–91].
Evidence on its use in ocular infections is still limited, but initial results are 
encouraging. Sponsel et al. also describe a case of keratitis by Fusarium solani resistant 
to Amphotericin B and natamycin but successfully treated with topical drop (100 mg/
ml prepared from an oral solution) associated with oral posaconazole 200 mg 4 times 
daily [89]. However, comparative controlled studies with first-line antifungal agents 
are still lacking. Altun et al. reported successful treatment with posaconazole in two 
cases with recalcitrant fugal keratitis that were resistant to conventional antifungal 
drugs (systemic and topical fluconazole or voriconazole and amphotericin B and topi-
cal natamycin were all ineffective) [90]. Posaconazole use resulted in rapid resolution 
of infection in these cases without significant toxicity. Posaconazole can be useful in 
cases of fungal keratitis that are resistant to standard antifungal therapy. However, 
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the use of topical posaconazole as monotherapy needs to be evaluated as well as the 
optimum effective concentration has to be standardized. Two different concentration 
of the topical preparation is used in the above studies.
4.6 Echinocandins
Echinocandins (caspofungin and micafungin) are semisynthetic lipopeptides 
act by inhibiting the synthesis of glucan in the fungal cell wall causing osmotic 
imbalance and cell lysis. Matsumoto et al. have reported successful use of topical 
0.2% micafungin in cases of refractory fungal keratitis [92]. In another study by 
Matsumoto et al. usiing topical micafungin 1 mg/ml reported found an efficacy 
comparable or superior to fluconazole in the treatment of keratitis by Candida albi-
cans and Candida parapsilosis [93]. Topical caspofungin has been used in the cases of 
fungal keratitis refractory to voriconazole [94]. There are limited data on the use of 
echinocandins to treat fungal keratitis in humans.
5. Recent advances in surgical treatment
Surgical intervention may be an option for patients with refractory FK not 
responding to medical treatment and severe fungal infections. Penetrating kera-
toplasty is considered the most common surgical intervention for serious fungal 
keratitis and cases with perforation or impending perforation. Recent advances 
have added more options such as targeted drug delivery at the site of infection in 
the form of intrastromal injections, collagen cross-linking and rose Bengal aided 
photodynamic therapy.
5.1 Intrastromal voriconazole
The efficacy of topical, as well as systemic, voriconazole is well established. Intra 
stromal voriconazole has been found as an effective approach for targeted drug 
delivery in the management of deep FK not responding to standard topical therapy 
[95–97]. Targeted drug delivery overcomes the issue of poor bioavailability of drugs 
in cases of deep fungal keratitis. It provides a depot of drug, close to the infected 
area. However, risk of introducing a new infection, inadvertent anterior chamber 
entry while performing the procedure in a hazy cornea are associated.
5.2 Intracameral amphotericin B
Intracameral Amphotericin B is another approach for targeted drug delivery, 
indicated when medical treatment with topical and systemic antifungal has failed, 
especially in cases with deep mycosis, endothelial plaque and presence of hypopyon 
with inflammation of the anterior chamber. The concentration injected, ranges 
between 5 and 10 μg/0.1 ml [98, 99].
5.3 Penetrating Keratoplasty
Penetrating Keratoplasty (PK) is indicated for treatment of refractory or severe 
fungal keratitis, corneal thinning and perforation in FK [100]. A retrospective 
study including 52 eyes which underwent PK for corneal perforations secondary 
to FK, reported improved visual acuity in 46 eyes (88.5%) and clear grafts in 44 
eyes (84.6%) at final follow-up [101]. The common complications of PK are graft 
rejection, recurrence of infection, and secondary glaucoma. Following PK, oral and 
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topical antifungal medications are usually continued for 2 weeks and if pathology 
reports presence of fungus on the margin of the cornea sample, treatment continues 
for 6–8 weeks.
Cyclosporine has been recommended after PK in cases of fungal keratitis as 
it has been suggested to have dual antifungal and anti-immune properties [102]. 
However; evidences at present are limited, further studies are required to evaluate 
the risk and benefit of cyclosporine patients undergoing corneal transplant for 
fungal keratitis.
5.4 Amniotic membrane transplantation
Amniotic membrane transplantation (AMT) has emerged as an option to delay 
or prevent PK secondary to fungal keratitis. Amniotic membranes have been used 
to facilitate ocular surface reconstructions in other ocular surface conditions. AMT 
support re-epithelialization of tissue, and the active components present in the 
membrane like nerve growth factors are thought to reduce pain [103]. In a study, 
23 culture-proven, acute fungal keratitis patients with non-healing corneal ulcers, 
or impending corneal perforation underwent AMT to prevent PK or to promote re-
epithelialization. Following AMT, 25% of patients with persistent positive culture 
for fungus required PK. The final visual outcome was BCVA > 20/400. It improved 
in 17, did not changed in four and worsened in two patients [104].
In an inflamed eye, there is increased risk of infection to be introduced into the 
anterior chamber or vitreous after PK and the use of corticosteroids, to prevent 
corneal graft rejection, may increase the risk of recurrence of fungal infection. 
Delay in PK can avoid these complications.
5.5 Lamellar Keratoplasty
Lamellar keratoplasty (LK) is emerged as an alternate surgical procedure for 
fungal keratitis in which only diseased layers of the corneal surface are excised and 
replaced by donor cornea. In a study from China, reported the leading indication 
for LK in 2008 was infectious keratitis, and fungal keratitis constituted 67% of the 
infectious keratitis cases [105]. In another study, 55 antifungal refractory patients 
underwent LK with intensive topical and oral antifungal medication. In 93% of 
the patients, the fungal infection was eradicated. The remaining four patients were 
treated by a secondary PK. Visual acuity ranged from 20/20 to 20/63 with a few 
complications after 6–18 months follow-up [106].
5.6 Corneal collagen cross-linking (riboflavin with ultraviolet-A irradiation)
Corneal collagen cross-linking (CXL) has been found successful in halting the 
progression of keratoconus by using riboflavin and UV-A light. In recent years, 
role of CXL in infectious keratitis is investigated in several studies with conflicting 
results on the efficacy of CXL in infectious keratitis [107–113]. Specifically the term 
photoactivated chromophore cross-linking (PACK-CXL) is used for CXL to treat 
infectious keratitis [108].
CXL may act in cases of fungal keratitis by a direct antifungal effect and by halt-
ing the ongoing melting, thus helping to avoid emergency keratoplasty [109–111]. 
Said et al. found that although PACK-CXL did not shorten the time to corneal heal-
ing, it prevented corneal melting [107]. PACK-CXL is found to be useful in fungal 
keratitis [108–110]. Abbouda et al. reported halting of corneal melting with PACK-
CXL in one case while the other developed perforation [112]. The safety of CXL is of 
concern because the ultraviolet (UV) -A could damage intraocular structures. Spoerl 
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et al. analyzed the expected damage compared with acceptable damage thresholds. 
During standard CXL of a cornea with a 400-μm thickness, the irradiances of the UV 
light reaching the iris, lens, and retina are less than the damage thresholds, and only 
the microbes, the corneal endothelium, and the keratocytes are at risk [113]. Minor 
complications after CXL, like transient limbitis and a transient increase in the size of 
the hypopyon in the first 24 h after CXL reported to be regress subsequently [107].
5.7 Rose Bengal photodynamic therapy
Photodynamic therapy (PDT) has been used in treatment of choroidal neovas-
cularization in age-related macular degeneration, corneal neovascularization and in 
infectious keratitis due to Acanthamoeba [114]. PDT involves the activation of pho-
tosensitizers using light of varying wavelengths. Rose Bengal photodynamic therapy 
(RB-PDT) involved a photochemical process using Rose Bengal, excited with green 
light (wavelength: 500–550 nm) to generate reactive oxygen species (ROS), which, 
react with various intracellular components to cause cell death. In an in vitro study, 
Arboleda et al. have demonstrated RB PDT to be successful in fungal keratitis [115].
In a pilot clinical study by Naranjo et al., RB-PDAT was performed in 18 patients 
with progressive infectious keratitis unresponsive to standard medical therapy. 
RB-PDAT was considered successful in 13 individuals, defined as control of infec-
tion without the need for a therapeutic PK [116]. Amescua G et al. in an vitro and 
in a case study evaluated the efficacy of rose bengal photodynamic antimicrobial 
therapy (PDAT). They found that Riboflavin CXL demonstrated no inhibition of 
fungal isolate growth, whereas rose bengal PDAT inhibited fungal isolate growth 
within the irradiation zone. In addition, a case with resistant fusarium keratitis was 
treated successfully [117].
6. Future perspective
6.1 New targets in immunology
In a study, the role of vitamin D receptor (VDR) in innate immunity being 
discovered, may be a new target of treatment that can be explored for FK [118].
Liposomes-encapsulated mannan extracts from C. albicans stimulate the produc-
tion of antibodies protective against candidiasis in mice [119]. Probiotics, such as 
L. rhamnosus, L. acidophilus, L. pyogenes, L. casei GG and Bifidobacterium, reported 
to be protective from candidiasis by eliciting protective immune and non-immune 
responses in mice [120]. These experimental studies may further facilitate 
researches to develop fungal keratitis vaccine and use of probiotics in ocular surface 
for diseases prevention.
6.2 Ocular novel drug delivery system
Recently, many efforts have been made to improve topical ocular drug delivery 
by designing various novel drug delivery systems (NDDS), including liposomes, 
nanoparticles, nanoemulsions, nanosuspensions, micelles, nanofibers, etc.
Several in vitro and in vivo experimental studies have reported encouraging 
results with NDDS. In a study, the liposomal formulation of the antifungal drug 
voriconazole found to exhibit a sustained drug release profile, and an 8-fold 
increase in the amount of drug retained in the cornea after 1 hour of exposure 
compared with the conventional suspension formulation [121]. The nanoparticle 
formulation of amphotericin B showed a sustained and controlled drug release for 
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up to 11 hours, while the conventional drug formulation (0.15%) released the entire 
drug in only 4 hours. Nanoparticle formulation has also shown better pharmaco-
kinetic properties, including 1.5-fold increase in half-life compared to the conven-
tional solution formulation [122]. The microemulsion formulations of fluconazole 
showed a controlled release profile, releasing 50–80% of the drug in 12 hours, 
compared to the conventional drug solution, which released almost the entire drug 
in the first 6 hours [123]. In future, these newer formulations can be very useful in 
management of fungal keratitis.
6.3 Antimicrobial peptides
Antimicrobial peptides (AMPs) have significant potential for use as antimicro-
bial agents for ocular or other infections [124]. AMPs, also known as host defense 
peptides, are naturally produced, small, cationic, amphiphilic peptides ranging in 
length from 12 to 50 amino acids. They are present on the surfaces of the eyes and in 
tears. More than 500 AMPs have been reported, including large molecules (RNases 
and S100A proteins); small peptides α and β defensins in human cationic antibacte-
rial protein (CAP) 18, and α 37 amino acids; proteins like lysozyme and peptidogly-
can recognition protein with significant bactericidal activity. The cations carried by 
AMPs can bind to the anion surface of the bacterial plasma membrane, causing the 
perforation of cell membrane and subsequently microbial death. AMPs also prevent 
microbial adhesion to and access into host cells and cause digestion of fungal cell 
wall by lysozyme [124, 125].
In vitro studies have shown AMPs Pc-C and Pc-E reduced binding of Aspergillus 
fumigatus to cells; CAP37 inhibits candida infection by fungicidal activity [124, 125]. 
Wu et al. evaluated in vivo application of synthetic β-sheet forming peptide (IKIK) 
2-NH2 and (IRIK) 2-NH2 for treatment of FK in comparison with amphotericin B 
[126]. It was found that topical solutions of the designed peptides were safe, and as 
effective as the clinically-used Amphotercin B. Many other AMPs such as Clavanin 
A, Chitinase 3-like 1, and CXCL 10 and S100 proteins may have role in prevention 
of infection.
7. Conclusion
Early diagnosis and treatment of fungal keratitis remains a challenge. A better 
understanding of pathogenesis can broadened the approach to management. Recent 
advances in techniques such as in vivo confocal microscopy and the evolution of 
PCR and MDS can useful in rapid and accurate diagnosis. Newer antifungal agents 
and newer methods of targeted drug delivery system can be helpful in treating 
refractory cases and improving outcome. New evolving technique like PACK-CXL 
and RB-PDT can be useful as adjuvant therapy.
New researches are continue to investigate the new aspects of pathogenesis, to 
device the novel drug delivery system to overcome the poor ocular penetration of 
antifungal drugs and enhance their efficacy and evaluate newer antifungal drugs. 
In recent years focus on modifying the immune response to the infection, thereby 
reducing the corneal melting and scarring which lead to poor vision, may have the 
greatest potential to improve visual outcomes.
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